Search

Your search keyword '"Gianni, Am"' showing total 456 results
Start Over Author "Gianni, Am"
456 results on '"Gianni, Am"'

1. A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma

Author

Derenzini E, Mazzara S, Melle F, Motta G, Fabbri M, Bruna R, Agostinelli C, Cesano A, Corsini CA, Chen N, Righi S, Sabattini E, Chiappella A, Calleri A, Fiori S, Tabanelli V, Cabras A, Pruneri G, Vitolo U, Gianni AM, Rambaldi A, Corradini P, Zinzani PL, Tarella C, Pileri S., and Derenzini E, Mazzara S, Melle F, Motta G, Fabbri M, Bruna R, Agostinelli C, Cesano A, Corsini CA, Chen N, Righi S, Sabattini E, Chiappella A, Calleri A, Fiori S, Tabanelli V, Cabras A, Pruneri G, Vitolo U, Gianni AM, Rambaldi A, Corradini P, Zinzani PL, Tarella C, Pileri S.

Subjects
NFKBIA, Diffuse Large B-cell Lymphoma, BCL-2, MYC, Gene expression profiling
Abstract

Recent randomized trials focused on gene expression-based determination of the cell of origin in diffuse large B-cell lymphoma could not show significant improvements by adding novel agents to standard chemoimmunotherapy. The aim of this study was the identification of a gene signature able to refine current prognostication algorithms and applicable to clinical practice. Here we used a targeted gene expression profiling panel combining the Lymph2Cx signature for cell of origin classification with additional targets including MYC, BCL-2 and NFKBIA, in 186 patients from 2 randomized trials (discovery cohort) (NCT00355199 and NCT00499018). Data were validated in 3 independent series (2 large public datasets and a real-life cohort). By integrating the cell of origin, MYC/BCL-2 double expressor status and NFKBIA expression, we defined a 3-gene signature combining MYC, BCL-2 and NFKBIA (MBN-signature), which outperformed the MYC/BCL-2 double expressor status in multivariate analysis, and allowed further risk stratification within the germinal center B-cell/unclassified subset. The high-risk (MBN Sig-high) subgroup identified the vast majority of double hit cases and a significant fraction of Activated B-Cell-derived diffuse large B-cell lymphomas. These results were validated in 3 independent series including a cohort from the REMoDL-B trial, where, in an exploratory ad hoc analysis, the addition of bortezomib in the MBN Sig-high subgroup provided a progression free survival advantage compared with standard chemoimmunotherapy. These data indicate that a simple 3-gene signature based on MYC, BCL-2 and NFKBIA could refine the prognostic stratification in diffuse large B-cell lymphoma, and might be the basis for future precision-therapy approaches.

Published
2021

8. P62 Situs inversus viscerum and renal agenesis in a newborn

Author

L. Soldano, Popolo G, S. Gorgoglione, Massimo Pettoello-Mantovani, G Nardella, GF Maffei, V Verrotti di Pianella, Di Gianni Am, C. Calabrese, Lozupone S, Villani G, Magaldi R, Candela Ma, and A Lanzano

Subjects
Dextrocardia, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, business.industry, Foramen secundum, Kartagener Syndrome, Horseshoe kidney, medicine.disease, Hypoplasia, Surgery, Situs inversus, Agenesis, otorhinolaryngologic diseases, medicine, business, Renal agenesis
Abstract

Situs inversus viscerum is a rare congenital anomaly (incidence 1/15–20 000) in which organs are mirrored from their normal positions. It is called situs inversus viscerum totalis when there is a total transposition of abdominal and thoracic viscera. Incomplete situs inversus viscerum involves transposition only of abdominal organs and is more frequently associated with congenital cardiac defects (90%–95% vs 5%–10% in situs inversus totalis). About 25% of individuals with situs inversus have an underlying condition known as Kartagener Syndrome. As a result of benign pathology, patients with situs inversus viscerum can live normal healthy lives. Situs viscerum inversus can be associated with defects in various organ systems (respiratory, GI tract, genitourinary). In literature there’s evidence of cases of situs inversus associated with renal malformations (dysplasia, hypoplasia, ectopia, polycystic kidney, horseshoe kidney). Association with renal agenesis is rare. We report the case of S., born at 40 weeks, eutocic delivery. APGAR 8/9, weight 3350 g. Normal fetal US. In the third day of life, heart sounds better heard on the right side of the chest. Cardiac US: situs inversus viscerum, dextrocardia, subaortic stenosis, restrictive ventricular septal defect, atrial septal defect ostium secundum. In the fourth day of life, abdominal US findings were suggestive of right renal agenesis. In the 20th day of life, right reducible inguinal hernia. The little patient underwent cystography, negative for vesicoureteral reflux, and static renal scintigraphy with evidence of absent activity in right renal space. Renal function, cerebral US, audiologial assessment and karyotype were normal. No respiratory distress reported. Mucociliary clearance test and a regular follow-up are scheduled.

Published
2017
Full Text
View/download PDF

9. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

Author

Tarella, Corrado, Zanni, M, DI NICOLA, M, Patti, C, Calvi, R, Pescarollo, A, Zoli, V, Fornari, A, Novero, D, Cabras, A, Stella, M, Comino, A, Remotti, D, Ponzoni, M, Caracciolo, D, Ladetto, Marco, Magni, M, Devizzi, L, Rosato, Rosalba, Boccadoro, Mario, Bregni, M, Corradini, P, Gallamini, A, Majolino, I, Mirto, S, Gianni, Am, GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI, Tarella, C, Zanni, M, Di Nicola, M, Patti, C, Calvi, R, Pescarollo, A, Zoli, V, Fornari, A, Novero, D, Cabras, A, Stella, M, Comino, A, Remotti, D, Ponzoni, Maurilio, Caracciolo, D, Ladetto, M, Magni, M, Devizzi, L, Rosato, R, Boccadoro, M, Bregni, M, Corradini, P, Gallamini, A, Majolino, I, Mirto, S, and Gianni, A.

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Lymphoma, B-Cell, Adolescent, medicine.medical_treatment, Transplantation, Autologous, Disease-Free Survival, Antibodies, Monoclonal, Murine-Derived, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Prospective Studies, Cyclophosphamide, Melphalan, Etoposide, Cisplatin, Peripheral Blood Stem Cell Transplantation, Chemotherapy, business.industry, Cytarabine, Antibodies, Monoclonal, Hematology, Middle Aged, medicine.disease, Combined Modality Therapy, Surgery, Lymphoma, Radiation therapy, Regimen, Treatment Outcome, Feasibility Studies, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, Mitoxantrone, business, Diffuse large B-cell lymphoma, medicine.drug
Abstract

A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/ cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged

Published
2007
Full Text
View/download PDF

10. Factors influencing the occurrence of secondary malignancies in high-risk lymphoma patients following high-dose therapy and autograft

Author

Tarella C, Passera R, Magni M, Rossi A, Benedetti F, Gueli A, Ruella M, Patti C, Parvis G, Gallamini A, Cortelazzo S, Corradini P, Zoli V, Mule A, Crocchiolo R, Bosa M, Barbui A, Di Nicola M, Caracciolo D, Sorio M, Gianni AM, Rambaldi A., CICERI , FABIO, Tarella, C, Passera, R, Magni, M, Rossi, A, Benedetti, F, Gueli, A, Ruella, M, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Corradini, P, Zoli, V, Mule, A, Crocchiolo, R, Bosa, M, Barbui, A, Di Nicola, M, Caracciolo, D, Sorio, M, Gianni, Am, and Rambaldi, A.

Published
2010

11. A recent update of 3 consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma shows a sizeable group of patients surviving in continuous complete remission

Author

Tarella C, Ladetto M, Benedetti F, Vitolo U, Pulsoni A, Patti C, Callea V, Rambaldi A, Piccin A, Devizzi L, Musso M, Iannitto E, Spedini P, Liberati AM, Gallamini A, Rodeghiero F, Gini G, De Crescenzo A, Di Raimondo F, Levis A, Chisesi T, Petrone T, Scalabrini DR, Rossi G, Carella AM, Parvis G, Majolino I, Passera R, Ruella M, Pileri A, Gianni AM, Corradini P., CICERI , FABIO, Tarella, C, Ladetto, M, Benedetti, F, Vitolo, U, Pulsoni, A, Patti, C, Callea, V, Rambaldi, A, Piccin, A, Devizzi, L, Musso, M, Iannitto, E, Spedini, P, Liberati, Am, Ciceri, Fabio, Gallamini, A, Rodeghiero, F, Gini, G, De Crescenzo, A, Di Raimondo, F, Levis, A, Chisesi, T, Petrone, T, Scalabrini, Dr, Rossi, G, Carella, Am, Parvis, G, Majolino, I, Passera, R, Ruella, M, Pileri, A, Gianni, Am, and Corradini, P.

Published
2010

13. TIME OF PERIPHERAL BLOOD PROGENITOR CELL COLLECTIONS MAY INFLUENCE THE RISK OF SECONDARY MYELODYSPLASTIC SYNDROME/ACUTE LEUKEMIA FOLLOWING INTENSIVE THERAPY AND AUTOGRAFT: A GITIL SURVEY ON 1,347 LYMPHOMA PATIENTS RECEIVING THE HIGH-DOSE SEQUENTIAL PROGRAM

Author

Tarella C, Zanni M, Magni M, Rossi A, Benedetti F, Passera R, Patti C, Parvis G, Gallamini A, Cortelazzo S, Majolino I, Barbui T, Mirto S, Corradini P, Boccadoro M, Saglio G, Pizzolo G, Rambaldi A, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Magni, M, Rossi, A, Benedetti, F, Passera, R, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Barbui, T, Mirto, S, Corradini, P, Boccadoro, M, Saglio, G, Pizzolo, G, Rambaldi, A, and Gianni, Am

Published
2008

14. Moderate risk of secondary myelodysplastic syndrome/acute leukaemia occurrence following highdose sequential chemotherapy and autograft: a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) survey on 1266 lymphoma patients

Author

Zanni M, Magni M, Rambaldi A, Benedetti F, Rosato R, Passera R, Patti K, Gallamini A, Cortellazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Andreini A, Barbui T, Gianni AM, Tarella C., CICERI , FABIO, Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Rosato, R, Passera, R, Patti, K, Ciceri, Fabio, Gallamini, A, Cortellazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Andreini, A, Barbui, T, Gianni, Am, and Tarella, C.

Published
2007

15. Update of a GITIL cohort study: Frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation induces a high rate of long-term remissions in patients with mantle cell lymphoma

Author

Cortelazzo S, Magni M, Tarella C, Mian M, Billio A, Rossi A, Marchesi M, Gallamini A, Corradini P, Parvis G, Majolino I, Patti C, Mirto S, Benedetti F, Pizzolo G, Gianni AM, Rambaldi A., CICERI , FABIO, Cortelazzo, S, Magni, M, Tarella, C, Mian, M, Billio, A, Rossi, A, Marchesi, M, Gallamini, A, Corradini, P, Ciceri, Fabio, Parvis, G, Majolino, I, Patti, C, Mirto, S, Benedetti, F, Pizzolo, G, Gianni, Am, and Rambaldi, A.

Published
2007

16. The risk of secondary myelodysplastic syndrome/acute leukemia following intensive therapy and autograft correlates with the type of cells grafted: A survey on 1,347 lymphoma patients receiving the high-dose sequential (HDS) program

Author

Zanni M, Magni M, Rambaldi A, Benedetti F, Passera R, Patti C, Parvis G, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Saglio G, Pizzolo G, Barbui T, Gianni AM, Tarella C., CICERI , FABIO, Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Passera, R, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Saglio, G, Pizzolo, G, Barbui, T, Gianni, Am, and Tarella, C.

Published
2007

17. Impact of complete remission achievement on the survival of lymphoma patients undergoing high-dose sequential chemotherapy and autograft (HDS programme): a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) retrospective study on 1,266 patients

Author

Tarella C, Zanni M, Rambaldi S, Magni M, Sorio M, Passera R, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Boccadoro M, Corradini P, Benedetti F, Barbui T, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Rambaldi, S, Magni, M, Sorio, M, Passera, R, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Boccadoro, M, Corradini, P, Benedetti, F, Barbui, T, and Gianni, Am

Published
2007

18. Reduced-intensity allogeneic stem cell transplantation is an effective salvage strategy for relapsed/refractory peripheral T-cell non-Hodgkin lymphomas

Author

Corradini P, Dodero A, Narni F, Fanin R, Matteucci P, Scime R, Farina L, Carniti C, Rambaldi A, Bonifazi F, Di Bartolomeo P, Olivieri A, Benedetti F, Console G, Angelucci E, Gianni AM, Tarella C., CICERI , FABIO, Corradini, P, Dodero, A, Narni, F, Fanin, R, Matteucci, P, Ciceri, Fabio, Scime, R, Farina, L, Carniti, C, Rambaldi, A, Bonifazi, F, Di Bartolomeo, P, Olivieri, A, Benedetti, F, Console, G, Angelucci, E, Gianni, Am, and Tarella, C.

Published
2007

19. Patients with aaIPI 2-3 diffuse large B-cell lymphoma achieve 75% long-term survival following first-line rituximab-supplemented high-dose sequential chemotherapy and autograft: Final results of the prospective phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) trial

Author

Tarella C, Zanni M, Di Nicola M, Patti C, Castellino C, Crocchiolo R, Zoli V, Caracciolo D, Magni M, Boccadoro M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Di Nicola, M, Patti, C, Castellino, C, Crocchiolo, R, Zoli, V, Caracciolo, D, Magni, M, Boccadoro, M, Ciceri, Fabio, Corradini, P, Gallamini, A, Majolino, I, Mirto, S, and Gianni, Am

Published
2007

20. Long-term outcome of ric-allo SCT for myeloma

Author

Montefusco V, CICERI , FABIO, Peccatori J, Farina L, Olivieri A, Hoenstaufen K, Deliliers GL, Gianni AM, Bregni M, Corradini P., Montefusco, V, Ciceri, Fabio, Peccatori, J, Farina, L, Olivieri, A, Hoenstaufen, K, Deliliers, Gl, Gianni, Am, Bregni, M, and Corradini, P.

Subjects
Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue
Published
2007

21. Incidence and risk factors of secondary myelodysplastic syndromelacute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients

Author

Zanni M, Magni M, Rambaldi A, Benedetti F, Rosato R, Passera R, Patti K, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Andreini A, Barbui T, Gianni AM, Tarella C., CICERI , FABIO, Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Rosato, R, Passera, R, Patti, K, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Andreini, A, Barbui, T, Gianni, Am, and Tarella, C.

Published
2007

22. Rituximab markedly improves the efficacy of high-dose programmes with autograft for B-cell lymphoma: a multicentre GITIL survey on 957 patients

Author

Tarella C, Zanni M, Magni M, Benedetti F, Barbui T, Boccadoro M, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A., CICERI , FABIO, Tarella, C, Zanni, M, Magni, M, Benedetti, F, Barbui, T, Boccadoro, M, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Passera, R, Pizzolo, G, Gianni, Am, and Rambaldi, A.

Published
2007

23. Prolonged survival of lymphoma patients achieving complete remission following high-dose sequential chemotherapy and autograft (HDS program): A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) retrospective study on 1,266 patients

Author

Tarella C, Zanni M, Rambaldi A, Magni M, Sorio M, Passera R, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Boccadoro M, Corradini P, Benedetti F, Barbui T, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Rambaldi, A, Magni, M, Sorio, M, Passera, R, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Boccadoro, M, Corradini, P, Benedetti, F, Barbui, T, and Gianni, Am

Published
2006

24. Benefit of rituximab addition to high-dose programs with autograft for B-cell lymphoma: A multicenter GITIL survey on 957 patients

Author

Tarella C, Zanni M, Magni M, Benedetti F, Barbui T, Boccadoro M, Patti K, Gallamini A, Cortelazzo S, Zoli V, Mirto S, Passera R, Corradini P, Pizzolo G, Gianni AM, Rambaldi A., CICERI , FABIO, Tarella, C, Zanni, M, Magni, M, Benedetti, F, Barbui, T, Boccadoro, M, Patti, K, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Zoli, V, Mirto, S, Passera, R, Corradini, P, Pizzolo, G, Gianni, Am, and Rambaldi, A.

Published
2006

25. Incidence of secondary myelodysplastic syndrome/acute leukemia in 1,266 lymphoma patients following high-dose therapy and autograft: A study from GITIL (Gruppo italiano terapie innovative nei linfomi)

Author

Zanni M, Magni M, Rambaldi A, Benedetti F, Rosato R, Passera R, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Andreini A, Barbui T, Gianni AM, Tarella C., CICERI , FABIO, Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Rosato, R, Passera, R, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Andreini, A, Barbui, T, Gianni, Am, and Tarella, C.

Published
2006

26. Reduced-intensity conditioning (RIC) followed by allogeneic stem cell transplantation (SCT) for relapsed lymphomas: Impact of pre-transplantation factors on long-term outcome

Author

Corradini P, Dodero A, Bregni M, Olivieri A, Farina L, Valagussa P, Scime R, Locasciulli A, Patriarca F, Gianni AM, Tarella C., CICERI , FABIO, Corradini, P, Dodero, A, Bregni, M, Ciceri, Fabio, Olivieri, A, Farina, L, Valagussa, P, Scime, R, Locasciulli, A, Patriarca, F, Gianni, Am, and Tarella, C.

Published
2005

27. Effect of age and previous autologous transplantation on treatment-related mortality and graft-versus-host disease in 110 patients treated with reduced-intensity conditioning and allografting for advanced haematological malignancies

Author

Corradini, P., Zallio, F., Jacopo Mariotti, Bregni, M., Ciceri, F., Bacigalupo, A., Dodero, A., Lucesole, M., Patriarca, F., Rambaldi, A., Scime, R., Majolino, I., Bandini, G., Gianni, Am, Tarella, C., Olivieri, A., Corradini, P, Zallio, F, Mariotti, J, Bregni, M, Ciceri, Fabio, Bacigalupo, A, Dodero, A, Lucesole, M, Patriarca, F, Rambaldi, A, Scime, R, Majolino, I, Bandini, G, Gianni, Am, Tarella, C, and Olivieri, A.

Published
2004

28. Effect of age and previous autologous transplant on treatment-related mortality and GVHD in 140 patients treated with reduce-intensity conditioning and allograft for advanced hematological malignancies

Author

Corradini P, Zallio F, Mariotti J, Valagussa P, Dodero A, Bregni M, Bacigalupo A, Lucesole M, Patriarca F, Rambaldi A, Scime R, Bandini G, Gianni AM, Tarella C, Olivieri A., CICERI , FABIO, Corradini, P, Zallio, F, Mariotti, J, Valagussa, P, Dodero, A, Bregni, M, Ciceri, Fabio, Bacigalupo, A, Lucesole, M, Patriarca, F, Rambaldi, A, Scime, R, Bandini, G, Gianni, Am, Tarella, C, and Olivieri, A.

Published
2004

29. Graft-versus-lymphoma effect in peripheral T-cell lymphomas (PTCL): Reduced-intensity conditioning followed by allogeneic transplantation gives a better outcome than high-dose chemotherapy followed by autografting

Author

Corradini P, Dodero A, Zallio F, Cuttica A, Caracciolo D, Di Nicola M, Casini M, Narni F, Patriarca F, Boccadoro M, Gianni AM, Tarella C., CICERI , FABIO, Corradini, P, Dodero, A, Zallio, F, Cuttica, A, Caracciolo, D, Di Nicola, M, Casini, M, Ciceri, Fabio, Narni, F, Patriarca, F, Boccadoro, M, Gianni, Am, and Tarella, C.

Published
2003

31. Reduced-intensity conditioning with low dose ATG or alemtuzumab followed by allogeneic PBSC: A salvage therapy with an encouraging response rate and limited toxicity in relapsed/refractory multiple myeloma

Author

Corradini P, Milani R, Montefusco V, Peccatori J, Mariotti J, Olivieri A, Soligo D, Gianni AM, Perfetti V, Bregni M., CICERI , FABIO, Corradini, P, Milani, R, Ciceri, Fabio, Montefusco, V, Peccatori, J, Mariotti, J, Olivieri, A, Soligo, D, Gianni, Am, Perfetti, V, and Bregni, M.

Published
2002

32. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients

Author

Zinzani, Pl, Martelli, M, Bertini, M, Gianni, Am, Devizzi, L, Federico, M, Pangalis, G, Michels, J, Zucca, E, Cantonetti, M, Cortelazzo, S, Wotherspoon, A, Ferreri, Aj, Zaja, Francesco, Lauria, F, De Renzo, A, Liberati, Ma, Falini, B, Balzarotti, M, Calderoni, A, Zaccaria, A, Gentilini, P, Fattori, Pp, Pavone, E, Angelopoulou, Mk, Alinari, L, Brugiatelli, M, Di Renzo, N, Bonifazi, F, Pileri, Sa, Cavalli, F, International Extranodal Lymphoma Study Group, Zinzani, Pl, Martelli, M, Bertini, M, Gianni, Am, Devizzi, L, Federico, M, Pangalis, G, Michels, J, Zucca, E, Cantonetti, M, Cortelazzo, S, Wotherspoon, A, Ferreri, Aj, Zaja, Francesco, Lauria, F, De Renzo, A, Liberati, Ma, Falini, B, Balzarotti, M, Calderoni, A, Zaccaria, A, Gentilini, P, Fattori, Pp, Pavone, E, Angelopoulou, Mk, Alinari, L, Brugiatelli, M, Di Renzo, N, Bonifazi, F, Pileri, Sa, Cavalli, F, and International Extranodal Lymphoma Study, Group

Subjects
response rate, Author Keywords:PMLBCL, chemotherapy, radiotherapy, combined modality treatment KeyWords Plus:HIGH-DOSE CHEMOTHERAPY, NON-HODGKINS-LYMPHOMA, MACOP-B, COMBINATION CHEMOTHERAPY, MALIGNANT-LYMPHOMA, RADIATION-THERAPY, CLINICAL-TRIALS, TRANSPLANTATION, CLASSIFICATION, MANAGEMENT
Abstract

BACKGROUND AND OBJECTIVES: This multinational retrospective study compares the outcomes of patients with primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis after first-generation (dose-intensive regimens), third-generation (alternating regimens) and high-dose chemotherapy strategies, frequently with adjuvant radiation therapy. DESIGN AND METHODS: Between August 1981 and December 1999, a total of 426 previously untreated patients with confirmed diagnosis were enrolled in 20 institutions to receive combination chemotherapy with either first generation (CHOP or CHOP-like) regimens, third generation (MACOP-B, VACOP-B, ProMACE CytaBOM) regimens or high-dose chemotherapy (HDS/ABMT). RESULTS: With chemotherapy, complete response (CR) rates were 49% (50/105), 51% (142/277) and 53% (23/44) with first generation, third generation and high-dose chemotherapy strategies, respectively; partial response (PR) rates were 32%, 36% and 35%, respectively. All patients who achieved CR and 124/142 (84%) with PR had radiation therapy on the mediastinum. The final CR rates became 61% for CHOP/CHOP-like regimens, 79% for MACOP-B and other regimens, and 75% for HDS/ABMT. After median follow-ups from attaining CR of 48.5 months for CHOP/CHOP-like regimens, 51.7 months for MACOP-B type regimens and 32.4 months for HDS/ABMT, relapses occurred in 15/64 (23%), 27/218 (12%) and 0/33 (0%) patients, respectively. Projected 10-year progression-free survival rates were 35%, 67% and 78%, respectively (p=0.0000). Projected 10-year overall survival rates were 44%, 71% and 77%, respectively (p=0.0000), after median follow-ups from diagnosis of 52.3 months, 54.9 months and 35.8 months, respectively. INTERPRETATION AND CONCLUSIONS: In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy may be a better strategy than other treatments; these retrospective data need to be confirmed by prospective studies. The encouraging survival results after high dose chemotherapy require confirmation in selected high-risk patients.

Published
2002

35. Reduced intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in leukemias and lymphomas

Author

Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Moira L, Dodero A, Rambaldi A, Sajeva MR, Tresoldi MIO, Bregni M., CICERI , FABIO, BORDIGNON, CLAUDIO, Corradini, P, Tarella, C, Olivieri, A, Gianni, Am, Voena, C, Zallio, F, Ladetto, M, Falda, M, Moira, L, Dodero, A, Ciceri, Fabio, Rambaldi, A, Sajeva, Mr, Tresoldi, Mio, Bordignon, Claudio, and Bregni, M.

Published
2001

39. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

Author

Ladetto, M, DE MARCO, F, Benedetti, F, Vitolo, U, Patti, C, Rambaldi, A, Pulsoni, Alessandro, Musso, M, Liberati, Am, Olivieri, A, Gallamini, A, Pogliani, E, Scalabrini, Dr, Callea, V, DI RAIMONDO, F, Pavone, V, Tucci, A, Cortelazzo, S, Levis, A, Boccadoro, M, Majolino, I, Pileri, A, Gianni, Am, Passera, R, Corradini, P, Tarella, C, GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO GITMO, INTERGRUPPO ITALIANO LINFOMI IIL, Foa, Roberto, Ladetto, M, De Marco, F, Benedetti, F, Vitolo, U, Patti, C, Rambaldi, A, Pulsoni, A, Musso, M, Liberati, A, Olivieri, A, Gallamini, A, Pogliani, E, Scalabrini, D, Callea, V, Di Raimondo, F, Pavone, V, Tucci, A, Cortelazzo, S, Levis, A, Boccadoro, M, Majolino, I, Pileri, A, Gianni, A, Passera, R, Corradini, P, and Tarella, C

Subjects
Male, Lymphoma, Follicular lymphoma, Salvage therapy, PREDICTIVE MODEL, Kaplan-Meier Estimate, INDOLENT LYMPHOMA, CHOP, Biochemistry, Gastroenterology, Antibodies, Monoclonal, Murine-Derived, Risk Factors, MED/15 - MALATTIE DEL SANGUE, hemic and lymphatic diseases, BONE-MARROW-TRANSPLANTATION, TERM-FOLLOW-UP, DOSE SEQUENTIAL CHEMOTHERAPY, STEM-CELL TRANSPLANTATION, NON-HODGKINS-LYMPHOMA, PROGRESSION-FREE SURVIVAL, MINIMAL RESIDUAL DISEASE, UNTREATED PATIENTS, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Medicine, Prospective Studies, Treatment Failure, Lymphoma, Follicular, Antibodies, Monoclonal, Hematology, Middle Aged, Rituximab, prognosis, Transplantation, Autologou, Treatment Outcome, Female, Survival Analysi, Immunotherapy, medicine.drug, Human, Adult, medicine.medical_specialty, Adolescent, Immunology, Transplantation, Autologous, Chemoimmunotherapy, Internal medicine, Humans, Proportional Hazards Models, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, Risk Factor, Cell Biology, Phosphamide, medicine.disease, Survival Analysis, Surgery, Transplantation, Feasibility Studie, Prospective Studie, Proportional Hazards Model, Feasibility Studies, business
Abstract

In this randomized multicenter study of 136 patients, 6 courses of CHOP (cyclo-phosphamide/doxorubicin/vincristine/prednisone) followed by rituximab (CHOP-R) were compared with rituximab-supplemented high-dose sequential chemotherapy with autografting (R-HDS) to assess the value of intensified chemo-therapy as a first-line treatment for high-risk follicular lymphoma (FL) after the introduction of monoclonal antibodies. The analysis was intention to treat with event-free survival (EFS) as the primary endpoint. Complete remission (CR) was 62% with CHOP-R and 85% with R-HDS (P < .001). At a median follow-up (MFU) of 51 months, the 4-year EFS was 28% and 61%, respectively (P < .001), with no difference in overall survival (OS). Molecular remission (MR) was achieved in 44% of CHOP-R and 80% of R-HDS patients (P < .001), and was the strongest independent outcome predictor. Patients relapsing after CHOP-R underwent salvage R-HDS in 71% of cases. Salvage R-HDS had an 85% CR rate and a 68% 3-year EFS (MFU, 30 months). We conclude that (1) achieving MR is critical for effective disease control, regardless of which treatment is used; (2) R-HDS ensures superior disease control and molecular outcome than CHOP-R, but no OS improvement; and (3) CHOP-R failures have a good outcome after salvage R-HDS, suggesting that relapsed/refractory FL could be the most appropriate setting for R-HDS–like treatments. This trial was registered at www.clinicaltrials.gov as no. NCT00435955.

Published
2008

43. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: Associations with presenting features and clinical outcome

Author

Rassidakis, GZ Medeiros, LJ Viviani, S Bonfante, V and Nadali, GP Vassilakopoulos, TP Mesina, O Herling, M and Angelopoulou, MK Giardini, R Chilosi, M Kittas, C and McLaughlin, P Rodriguez, MA Romaguera, J Bonadonna, G and Gianni, AM Pizzolo, G Pangalis, GA Cabanillas, F Sarris, AH

Subjects
hemic and lymphatic diseases
Abstract

Purpose: CD20 can be expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin’s disease (HD), but its clinical significance remains controversial. Therefore, we correlated CD20 expression with presenting features and clinical outcome of untreated patients with classical HID. Patients and Methods: Patients were eligible if they were previously untreated and human immunodeficiency virus-1 negative, had biopsy-proven classical HD, and if pretreatment paraffin-embedded tumor tissue was available. CD20 expression was determined by immunohistochemistry without knowledge of clinical outcome. A tumor was considered positive if any HRS cells expressed CD20, but other cutoffs for number of CD20-positive HRS were also investigated. Results: We identified 598 patients whose median age was 30 years and of whom 55% were male. HRS cells expressed CD20 in 132 (22%) of 598 patients with classical HD. When any percentage of CD20 expression in HRS cells was used as a cutoff, the 5-year failure-free survival (FFS) for positive versus negative tumors was 86% versus 84%, respectively, for 302 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens (P = .7 by log-rank test), 74% versus 77%, respectively, for 181 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = .7 by log-rank test), 74% versus 84%, respectively, for 54 patients treated with MOPP (P = .4 by log-rank test), and 77% versus 88% for 53 patients treated only with radiotherapy (P = .5 by log-rank test). The 5-year FFS was not statistically different when cutoffs of 5% up to 50% for CD20-positive HRS cells were used. Conclusion: CD20 is expressed by HRS cells in 22% of patients with classical HD but is not associated with different FFS after treatment with equivalent regimens. (C) 2002 by American Society of Clinical Oncology.

Published
2002

44. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma

Author

Cortelazzo, S, Rambaldi, A, Rossi, A, Oldani, E, Ghielmini, M, Benedetti, F, Tarella, Corrado, Zaglio, F, Vitolo, U, DI NICOLA, M, Pogliani, E, Cavalli, F, Gianni, Am, and Barbui, T.

Subjects
Adult, Male, Salvage Therapy, Adolescent, Lymphoma, Non-Hodgkin, Hematopoietic Stem Cell Transplantation, Middle Aged, Transplantation, Autologous, Disease-Free Survival, Drug Administration Schedule, Survival Rate, Methotrexate, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Humans, Regression Analysis, Female, Cyclophosphamide, Aged, Etoposide, Retrospective Studies
Abstract

The aim of the present study was to retrospectively evaluate whether a high-dose sequential chemotherapy programme (HDS: cyclophosphamide, methotrexate, etoposide) administered prior to autologous transplantation could optimize the salvage of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Between 1985 and 1999, 103 patients (median age 43 years, range 16-65) from eight Italian centres and one Swiss centre, with refractory (n = 38) or relapsed (n = 65) diffuse large B-cell and T-cell lymphoma, were treated using HDS followed by high-dose regimens with autologous haematopoietic stem cell transplantation. Eighty-three patients responded to the HDS regimen (81%, 95% C.I., 73- 88%) and 79 eventually achieved a complete response (CR) after autotransplantation (90%, 95% C.I., 81- 96%). None of 20 cases resistant to HDS attained CR. Treatment-related mortality was 4%. After a median follow-up of 24 months (range 6-174 months), 3-year estimates of overall survival, event-free survival and disease-free survival were 47% (95% C.I., 36-59%), 44% (95% C.I., 34-54%) and 64% (95% C.I., 50-74%) respectively. Multivariate analysis showed that chemosensitivity to HDS represented the strongest predictor of both CR and survival. This retrospective study shows that salvage treatment using HDS had relatively low toxicity and was associated with remarkable response rates, allowing further effective therapy with high-dose autograft programmes.

Published
2001

45. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

Author

Mian, M, Marcheselli, L, Luminari, S, Federico, M, Cantonetti, M, Sarris, A, Rossi, A, Rambaldi, A, Frontani, M, Devizzi, L, Gianni, A, Busetto, M, Berti, E, Martinelli, G, Tsang, R, Ferreri, A, Pinotti, G, Pogliani, E, Zucca, E, Cortelazzo, S, Sarris, AH, Gianni, AM, BERTI, EMILIO, Tsang, RW, Ferreri, AJM, POGLIANI, ENRICO MARIA, Cortelazzo, S., Mian, M, Marcheselli, L, Luminari, S, Federico, M, Cantonetti, M, Sarris, A, Rossi, A, Rambaldi, A, Frontani, M, Devizzi, L, Gianni, A, Busetto, M, Berti, E, Martinelli, G, Tsang, R, Ferreri, A, Pinotti, G, Pogliani, E, Zucca, E, Cortelazzo, S, Sarris, AH, Gianni, AM, BERTI, EMILIO, Tsang, RW, Ferreri, AJM, POGLIANI, ENRICO MARIA, and Cortelazzo, S.

Abstract

Indolent primary cutaneous B cell lymphomas (PCBCL) generally have a good prognosis, but they often relapse leading in some cases to extracutaneous disease and therefore, to poor survival. We developed a prognostic model to improve the therapeutic approach to these lymphomas. Two hundred and seventeen patients with diagnosis of indolent PCBCL stage IE or IIE were assessed retrospectively. The prognostic model was built to fit a Cox proportional hazard model using all the covariates affecting progression-free survival (PFS) at p<0.1 in the univariate analysis, and the final model was selected based on the Bayes Information Criteria. Elevated serum lactate dehydrogenase, morphology of the lesion (nodule vs. other), and >2 lesions were independent predictors for PFS. To each prognostic factor was assigned a value of 1. Patients were then stratified to three risk groups: score 0 (28%), low risk; score 1 (55%), intermediate risk; score 2 and 3 (17%), high risk with a 5-year PFS of 91%, 64%, and 48%, respectively (p<0.001). The CLIPI is an easily applicable prognostic index and represents a promising tool for risk-adapted treatment strategies. However, it needs to be addressed in prospective clinical studies.

Published
2011

46. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

Author

Viviani, S, Zinzani, P, Rambaldi, A, Brusamolino, E, Levis, A, Bonfante, V, Vitolo, U, Pulsoni, A, Liberati, A, Specchia, G, Valagussa, P, Rossi, A, Zaja, F, Pogliani, E, Pregno, P, Gotti, M, Gallamini, A, Rota Scalabrini, D, Bonadonna, G, Gianni, A, Zinzani, PL, Liberati, AM, Gianni, AM, POGLIANI, ENRICO MARIA, Viviani, S, Zinzani, P, Rambaldi, A, Brusamolino, E, Levis, A, Bonfante, V, Vitolo, U, Pulsoni, A, Liberati, A, Specchia, G, Valagussa, P, Rossi, A, Zaja, F, Pogliani, E, Pregno, P, Gotti, M, Gallamini, A, Rota Scalabrini, D, Bonadonna, G, Gianni, A, Zinzani, PL, Liberati, AM, Gianni, AM, and POGLIANI, ENRICO MARIA

Abstract

BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for advanced Hodgkin's lymphoma, in place of the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

Published
2011

47. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy

Author

Boccadoro, Mario, Tarella, C, Palumbo, A, Argentino, C, Triolo, S, Dominietto, A, Callea, V, Lauta, Vm, Molica, S, Musto, P, Marmont, F, Gianni, Am, and Pileri, A.

Subjects
Dose-Response Relationship, Drug, Plasma Cells, Antineoplastic Agents, Cell Count, Middle Aged, Severity of Illness Index, Disease-Free Survival, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Humans, Longitudinal Studies, Multiple Myeloma, beta 2-Microglobulin, Follow-Up Studies
Abstract

The clinical advantage of high-dose therapy (HDT) over standard treatment for multiple myeloma (MM) patients has been recently assessed. Which patient subgroups benefit most from this approach is unclear.To address this issue, the outcome of 54 patients under 55 years old treated with HDT was compared with that of 101 age-matched controls selected from 390 patients who received standard melphalan and prednisone (MP) chemotherapy in a national multi-center trial (M90 protocol).The complete response (CR) rate was 50% in the HDT group compared to 5% in the MP group. Event-free survival (EFS) was three times longer for the HDT patients (median 34.5 vs 12.2 months, p0. 0001), though the controls enjoyed a prolonged survival after relapse, and hence there was no statistically significant difference in OS. Overall survival (OS) was analyzed in relation to to two major prognostic factors: b(2)-microglobulin (b(2)-M) and bone marrow plasma cell labeling index (LI). HDT significantly improved OS in poor prognosis patients with a high LI (1.2%), (median 49.5 vs 32.5 months, p0.03), whereas it did not prolong OS in poor prognosis patients with high b(2 )-M (3 mg/L).In conclusion, HDT has a major impact on CR and EFS, and is the treatment of choice for patients with a high LI. Alternative strategies should be adopted in poor prognosis patients with high b(2 )-M.

Published
1999

48. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome

Author

Corradini, P, Dodero, A, Farina, L, Fanin, R, Patriarca, F, Miceli, R, Matteucci, P, Bregni, M, Scimè, R, Narni, F, Pogliani, E, Locasciulli, A, Milani, R, Carniti, C, Bacigalupo, A, Rambaldi, A, Bonifazi, F, Olivieri, A, Gianni, A, Tarella, C, Gianni, AM, Tarella, C., POGLIANI, ENRICO MARIA, Corradini, P, Dodero, A, Farina, L, Fanin, R, Patriarca, F, Miceli, R, Matteucci, P, Bregni, M, Scimè, R, Narni, F, Pogliani, E, Locasciulli, A, Milani, R, Carniti, C, Bacigalupo, A, Rambaldi, A, Bonifazi, F, Olivieri, A, Gianni, A, Tarella, C, Gianni, AM, Tarella, C., and POGLIANI, ENRICO MARIA

Abstract

The safety and efficacy of reduced-intensity conditioning (RIC) followed by allogeneic stem cell transplantation (SCT) for relapsed lymphomas remains unresolved. We conducted a prospective, multicentered, phase II trial. A total of 170 relapsed/refractory lymphomas received a RIC regimen followed by SCT from sibling donors. The primary study end point was non-relapse mortality (NRM). Histologies were non-Hodgkin's lymphomas (NHL) (indolent (LG-NHL), n=63; aggressive (HG-NHL), n=61; mantle cell lymphoma (MCL), n=14) and Hodgkin's disease (HD, n=32). Median follow-up was 33 months (range, 12-82). The results show that frequencies were as follows: cumulative NRM at 3 years, 14%; acute and chronic graft-versus-host disease (GVHD) 35 and 52%, respectively; 3-year overall survival (OS), 69% for LG-NHL, 69% for HG-NHL, 45% for MCL and 32% for HD (P=0.058); and 3-year relapse incidence, 29, 31, 35 and 81%, respectively (P<0.001). Relapse risk differed significantly at 3 years between follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (14 versus 46%, P=0.04). Molecular remission occurred in 94 and 40% (P=0.002) of patients with FL and CLL, respectively. On multivariate analysis, OS was influenced by chemorefractory disease (hazard ratio (HR)=3.6), diagnosis of HD (HR=3.5), and acute GVHD (HR=5.9). RIC allogeneic SCT is a feasible and effective salvage strategy in both indolent and aggressive NHL.

Published
2007

49. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas

Author

Passoni, L, Gallo, B, Biganzoli, E, Stefanoni, R, Massimino, M, Di Nicola, M, Gianni, A, GAMBACORTI PASSERINI, C, Gianni, AM, GAMBACORTI PASSERINI, CARLO, Passoni, L, Gallo, B, Biganzoli, E, Stefanoni, R, Massimino, M, Di Nicola, M, Gianni, A, GAMBACORTI PASSERINI, C, Gianni, AM, and GAMBACORTI PASSERINI, CARLO

Abstract

BACKGROUND AND OBJECTIVES: Anaplastic lymphoma kinase (ALK) oncogenic fusion proteins, expressed in about 60% of anaplastic large cell lymphomas (ALCL), are tumor-specific molecular targets for such a malignancy. One of the promising ALK-targeted therapeutic options is cancer vaccination. In this study, we investigate whether ALK is a tumor-associated antigen suitable for immune interventions. DESIGN AND METHODS: The frequency and the functional phenotype of the anti-ALK CD8 precursor repertoire in freshly isolated peripheral blood mononuclear cells (PBMC) from healthy donors and ALK-positive patients were determined by major histocompatibility complex (MHC)/tetrameric analyses. The anti-ALK secondary immune responses were evaluated as PBMC-specific interferon (INF-gamma) release by ELISPOT. In addition, the ability of the anti-ALK immune response to specifically lyse ALK-positive lymphoma cells was investigated by in vitro stimulation with ALK-derived peptide p280-89. RESULTS: Tetrameric MHC/peptide complexes revealed high frequencies of CD8/ALK-tetramer-positive cells both in patients and in healthy individuals. However, the functional phenotype of the CD8/ALK-tetramer-positive lymphocytes showed the presence of effector and memory T lymphocytes only in patients. The anti-ALK cytotoxic T lymphocytes (CTL) of patients, but not healthy donors, displayed thresholds of activation comparable to those of CTL precursors of a recall antigen (influenza virus). A polyclonal ALK-specific tumor-reactive T-cell line was isolated from patients' peripheral blood lymphocytes. INTERPRETATION AND CONCLUSIONS: The presence of an anti-ALK effector/memory lymphocyte population in the peripheral blood of ALK-positive patients indicates an in vivo antigenic challenge. Thus, ALK is a lymphoma-associated antigen suitable for immune interventions. The high number of anti-ALK memory CD8 T cells present in patients' PBMC may represent a valid source of activated CTL suitable for cancer cell

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results